Get the Stockscreener App
3.69
1.93%
0.07
Polypid Ltd stock is traded at $3.69, with a volume of 60,410.
It is up +1.93% in the last 24 hours and up +7.27% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.62
Open:
$3.65
24h Volume:
60,410
Relative Volume:
0.86
Market Cap:
$58.66M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.1876
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
+1.37%
1M Performance:
+7.27%
6M Performance:
+32.73%
1Y Performance:
+2.22%
1-Day Range:
$3.615
$3.74
1-Week Range:
$3.50
$3.74
52-Week Range:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.69 | 60.22M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.21 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.27 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.32 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.99 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.65 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid Ltd. to Host Virtual KOL Event on D-PLEX100 and Surgical Site Infection Prevention - Quiver Quantitative
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 - GlobeNewswire
How analysts rate PolyPid Ltd. stock todayJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
What makes PolyPid Ltd. stock attractive to growth fundsJuly 2025 Setups & Trade Opportunity Analysis Reports - newser.com
Top chart patterns to watch in PolyPid Ltd.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
PolyPid price target lowered to $9 from $10 at Roth Capital - MSN
Published on: 2025-11-19 04:16:34 - newser.com
Will PolyPid Ltd. stock outperform growth indexesJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Will PolyPid Ltd. rebound enough to break evenInsider Selling & Intraday High Probability Alerts - newser.com
Why PolyPid Ltd. stock could benefit from AI revolutionMarket Movement Recap & Risk Controlled Swing Trade Alerts - newser.com
What analysts say about PolyPid Ltd stockLong-Term Growth Stocks & Start Small. End Wealthy. - earlytimes.in
Roth Capital Issues Optimistic Estimate for PolyPid Earnings - Defense World
Published on: 2025-11-16 12:50:26 - newser.com
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - Defense World
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness - MSN
Using flow based indicators on PolyPid Ltd.July 2025 Summary & Proven Capital Preservation Methods - newser.com
Published on: 2025-11-13 18:14:47 - newser.com
Roth Capital Maintains PolyPid (PYPD) Buy Recommendation - Nasdaq
Is PolyPid Ltd. stock undervalued vs historical averagesJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
PolyPid (PYPD) Sees Price Target Cut by Roth Capital | PYPD Stoc - GuruFocus
PolyPid Ltd. (NASDAQ:PYPD) Q3 2025 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Advances Towards Key Milestones in 2025 - TipRanks
Published on: 2025-11-12 21:51:34 - newser.com
Leading vs lagging indicators on PolyPid Ltd. performanceOptions Play & Free Growth Oriented Trading Recommendations - newser.com
PolyPid Ltd. Earnings Call: Progress and Potential - TipRanks
PolyPid Ltd (PYPD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges By GuruFocus - Investing.com Canada
Earnings call transcript: PolyPid Q3 2025 shows mixed results, stock dips - Investing.com Australia
Transcript : PolyPid Ltd., Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
PolyPid : Investor Presentation (29305a) - MarketScreener
PolyPid Keeps Moving Forward Despite Quarterly Losses - Finimize
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results - The Manila Times
PolyPid Ltd. Advances Regulatory Strategy with FDA Pre-NDA Meeting and U.S. Partnership Discussions Following Positive Phase 3 Trial Results - Quiver Quantitative
Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln - MarketScreener
[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC FilingForm 6-K - Stock Titan
PolyPid (NASDAQ: PYPD) completes IMOH GMP inspection; FDA pre‑NDA set, NDA in 2026 - Stock Titan
PolyPid receives Nasdaq’s non-compliance letter - MSN
Why PolyPid Ltd. stock could rally in 20252025 Market Sentiment & Free Real-Time Market Sentiment Alerts - newser.com
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):